博雅生物1月9日获融资买入1734.47万元，融资余额6.83亿元

Group 1 - The core viewpoint of the news is that Boya Bio's stock performance and financing activities indicate a mixed outlook, with significant financing activity but a decline in net profit year-over-year [1][2]. - On January 9, Boya Bio's stock rose by 0.82%, with a trading volume of 110 million yuan. The financing buy-in amount was 17.34 million yuan, while the financing repayment was 35.24 million yuan, resulting in a net financing outflow of 17.89 million yuan [1]. - As of January 9, the total balance of margin trading for Boya Bio was 685 million yuan, with a financing balance of 683 million yuan, accounting for 5.76% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 31, Boya Bio had 30,100 shareholders, a slight decrease of 0.03% from the previous period, while the average circulating shares per person increased by 0.03% to 16,737 shares [2]. - For the period from January to September 2025, Boya Bio reported a revenue of 1.474 billion yuan, representing a year-over-year growth of 18.38%. However, the net profit attributable to the parent company was 343 million yuan, reflecting a year-over-year decrease of 16.90% [2]. - Boya Bio has distributed a total of 1.007 billion yuan in dividends since its A-share listing, with 489 million yuan distributed over the past three years [3].